Vicki L. Sato, Director at Denali Therapeutics Inc. (DNLI), sold 6,060 shares at $24.99 ($151K) on 2024-09-03, disclosed to the SEC on 2024-09-04.
Scheduled sale ($151k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.99 | 2,980 | $74K | 49.2% |
| 2 | $24.99 | 2,980 | $74K | 49.2% |
| 3 | $25.37 | 100 | $3K | 1.7% |
| Total | $25.00 avg | 6,060 | $151K | 100% |
| Filing → |
| VIR | SELL | 2026-03-03 | $416K | — | Filing → |
| VIR | SELL | 2026-02-26 | $825K | — | Filing → |
| VIR | SELL | 2026-02-03 | $170K | — | Filing → |